期刊文献+

艾他培南关键中间体的合成 被引量:6

Synthesis of (2S,4S)-4-acetylthio -1-(4-nitrobenzyloxycarbonyl) -2-(3-allyloxycarbonylphenylcarbamoyl) pyrr olidine
下载PDF
导出
摘要 目的改进艾他培南关键中间体(2S,4S)-4-乙酰硫-1-对硝基苄氧羰基-2-(3-烯丙氧羰基苯氨甲酰基)吡咯烷的合成工艺。方法以反-4-羟基-L-脯氨酸为原料经氨基、羧基保护;羟基甲磺酰化和乙酰硫化;脱去羧基保护基;与3-氨基苯甲酸烯丙酯缩合得目标物。结果与结论反-4-羟基-L-脯氨酸经6步反应制得目标物,总收率为49·4%,各步反应不需繁琐的柱色谱分离,操作简便,适合工业生产。 Aim To synthesize a key intermediate of ertapenem. Methods (2S, 4S )-4-acetylthio-1-( 4-nitrobenzyloxycarbonyl)-2- (3-allyloxycarbonylphenylcarbamoyl) pyrrolidine was efficiently synthesized from readily available trans-4-hydroxy-L-proline via six steps reactions. Results and conclusion The overall yield is 49.4 %. The process is convenient and simple for pharmaceutical manufacture.
出处 《中国药物化学杂志》 CAS CSCD 2006年第2期82-84,共3页 Chinese Journal of Medicinal Chemistry
关键词 药物化学 化合物制备 化学合成 艾他培南 碳青霉烯 medicinal chemistry compound preparation chemical synthesis ertapenem carbapenem
  • 相关文献

参考文献4

  • 1仲兆金,刘浚.新的碳青霉烯类抗生素[J].中国抗生素杂志,2004,29(4):196-202. 被引量:10
  • 2Sorbera LA,Rabasseda X,Castaner J,et al.MK-0826[J].Drugs Future,2000,25(8):795-802.
  • 3Sunagawa M,Matsumura H,Inoue T,et al.A novel carbapenem antibiotic,SM-7338 structure-activity relationships[J].J Antibiot,199.0,43(5):519-532.
  • 4Betts MJ,Davies GM,Swain ML.Antibiotic compounds[P].US:5856321,1999-01-05.

二级参考文献34

  • 1吴永乐.新的碳青霉烯类抗生素[J].国外医药(抗生素分册),1995,16(3):178-182. 被引量:8
  • 2Kahan J S. Kahan F M, Goegelman R, el al. Thienamycin, a new beta-lacram anlibiotic: 1. Discovery. taxonomy, isolation and physical properties [J]. ,J Amibiol.1979.32(1 ):1.
  • 3Kahan F M, Kropp H, Sundelof J G, et al. Thienamycin: Development of imipenem-cilastatin [J]. J Antimicrob Chemother, 1983,12 (Suppl D) : 1.
  • 4Peterson P J, Jacobus N V, Weiss W J, et al. In vitro and in vivo activities of LJC 10.627, a new carbapenem with stability to dehydropeptidase [J]. Antimicrob Agents Chemother, 1991,35(1 ) :203.
  • 5Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multirisistant Gram-negative clinical pathogens [J]. Antimicrob Agents Chemother, 1997,41 (8) : 1830.
  • 6Fuchs P C, Barry A L, Brown S D. et al. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 north American medical centers [J]. Antirnicrob Agents Cherm~ther, 2001,45 ( 6 ) : 1915.
  • 7Rosen H, Hajdu R, Silver 1., et al. Reduced immunotoxicity and preservation of anlibacterial activity in a releasable side-chain carbapenem antibiotic [J]. Science. 1999.283:70.3.
  • 8Sorbera L A, Rabsseda J, Castaner P A, et al. MK-0826 [J]. Drugs Fut,2000,25(8):795.
  • 9Ohtake N, Imamura H, Kiyonaga H, et al. Novel dithiocarbamate carbapenems with anti-MRSA activity [J]. Bioorg Med (?hbm Lett, 1997,7 ( 1:3 ) : 1617.
  • 10Sumita Y. Nouda H. Kanasawa K. et al. Antimicrobial activity of SM-17466. a novel carbapenem antibiotic with potent activity against methicillin-resistant .Staphylocoecus aureus [J]. Antimicrob Agents Chemother. 1995. 39(4):910.

共引文献9

同被引文献86

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部